Syndax Pharmaceuticals, Inc.
SNDX
SNDX: Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
moreShow SNDX Financials
Recent trades of SNDX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by SNDX's directors and management
Government lobbying spending instances
-
$20,000 Aug 12, 2020 Issue: Health Issues Government Issues
-
$80,000 Jul 19, 2020 Issue: Health Issues Government Issues
New patents grants
-
Patent Title: Selection of patients for combination therapy Jul. 26, 2022
-
Patent Title: Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer May. 10, 2022
-
Patent Title: Methods for the treatment of breast cancer Mar. 12, 2019
Federal grants, loans, and purchases
Followers on SNDX's company Twitter account
Number of mentions of SNDX in WallStreetBets Daily Discussion
Recent insights relating to SNDX
Recent picks made for SNDX stock on CNBC
ETFs with the largest estimated holdings in SNDX
Flights by private jets registered to SNDX